Disruption of adipocyte YAP improves glucose homeostasis in mice and decreases adipose tissue fibrosis

Daniel J. Han1,2, Rukhsana Aslam2, Paraish S. Misra1,2, Felix Chiu2, Tanvi Ojha2, Apu Chowdhury3, Carmen K. Chan1,2, Hoon-Ki Sung3, Darren A. Yuen1,2, Cynthia T. Luk1,2,*

ABSTRACT

Objective: Adipose tissue is a very dynamic metabolic organ that plays an essential role in regulating whole-body glucose homeostasis. Dysfunctional adipose tissue hypertrophy with obesity is associated with fibrosis and type 2 diabetes. Yes-associated protein 1 (YAP) is a transcription cofactor important in the Hippo signaling pathway. However, the role of YAP in adipose tissue and glucose homeostasis is unknown.

Methods: To study the role of YAP with metabolic stress, we assessed how increased weight and insulin resistance impact YAP in humans and mouse models. To further investigate the in vivo role of YAP specifically in adipose tissue and glucose homeostasis, we developed adipose tissue-specific YAP knockout mice and placed them on either chow or high fat diet (HFD) for 12–14 weeks. To further study the direct role of YAP in adipocytes we used 3T3-L1 cells.

Results: We found that YAP protein levels increase in adipose tissue from humans with type 2 diabetes and mouse models of diet-induced obesity and insulin resistance. This suggests that YAP signaling may contribute to adipocyte dysfunction and insulin resistance under metabolic stress conditions. On an HFD, adipose tissue YAP knockout mice had improved glucose tolerance compared to littermate controls. Perigonadal fat pad weight was also decreased in knockout animals, with smaller adipocyte size. Adipose tissue fibrosis and gene expression associated with fibrosis was decreased in vivo and in vitro in 3T3-L1 cells treated with a YAP inhibitor or siRNA.

Conclusions: We show that YAP is increased in adipose tissue with weight gain and insulin resistance. Disruption of YAP in adipocytes prevents glucose intolerance and adipose tissue fibrosis, suggesting that YAP plays an important role in regulating adipose tissue and glucose homeostasis with metabolic stress.

© 2022 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords Yes-associated protein; Adipose tissue; Insulin resistance; Obesity; Diabetes

1. INTRODUCTION

Adipose tissue is increasingly recognized as a dynamic metabolic organ capable of rapid remodeling to regulate nutrient excess or shortage [1]. It takes as little as one week of a high fat diet (HFD) in rodents for adipocytes to undergo massive expansion [2]. The weight of visceral adipose tissue can double with one week of HFD and then undergo a dramatic reduction with 24 h of fasting [3]. This plasticity contributes to the essential role of adipose tissue in maintaining metabolic homeostasis.

Increasingly, obesity with adipose tissue fibrosis has been associated with insulin resistance, potentially via reduced plasticity and increased lipotoxicity [4–6]. Increased extracellular matrix (ECM) components, collagen expression and fibrosis in human adipose tissue have been correlated with insulin resistance and higher triglyceride levels [4,5,7]. The mechanisms regulating adipose tissue fibrosis and glucose homeostasis are a rapidly evolving area of interest.

Yes-associated protein 1 (YAP) was first identified as a proline-rich phosphoprotein that binds to the Src homology domain 3 of the Yes proto-oncogene product [8]. Since then, it has been extensively studied in relation to its role in organ size, stem cell fate, and cancer [9–11]. Emerging evidence suggests an important role for Hippo signaling in fibrosis. YAP/TAZ have been identified as mechanosensors that play...
an important role in renal fibrogenesis; knocking out or pharmacological inhibition of YAP reduces renal fibrosis [12]. Lungs of patients with idiopathic pulmonary fibrosis show induced YAP and knocking down YAP reversed these profibrotic changes [13]. In liver fibrosis, YAP is activated in hepatic stellate cells in response to liver damage in vivo and ECM stiffening ex vivo. Importantly, knockdown of YAP expression and pharmacological inhibition of YAP both prevented hepatic stellate cell activation and impeded fibrogenesis in mice [14]. Studies to date of the Hippo signaling pathway and its downstream effectors in adipocytes have focused on adipogenesis, suggesting that in vitro, this pathway may regulate differentiation and proliferation in adipocytes [15,16]. In mature adipocytes in vivo, TAZ has been identified as a regulator of adipogenic activity, with deletion of TAZ in adipocytes resulting in improved glucose homeostasis [17]. Deletion of both YAP and TAZ impairs adipose tissue expansion in mice [18]. The specific role of YAP in mature adipocytes and in whole body glucose homeostasis is not known, and our goal is to characterize its role in adipose tissue, particularly in vivo and in the setting of obesity and type 2 diabetes.

In this study, we find that levels of YAP are increased in adipocytes from humans and mouse models with obesity and insulin resistance. To specifically study the role of YAP in whole body physiology and metabolic stress we generated novel adipocyte-specific YAP knockout mice. Deletion of YAP in fat cells improves glucose tolerance, particularly in the setting of diet-induced obesity and insulin resistance. Targeting YAP also resulted in decreased perigonalad fat pad weight, adipocyte size, and adipose tissue fibrosis. Inhibiting or knocking down YAP in 3T3-L1 adipocytes directly also decreases fibrogenic gene expression. Overall, this identifies an important new role for adipocyte YAP in regulating adiposity, glucose homeostasis, and adipose tissue fibrosis in the setting of obesity-associated insulin resistance.

### Table 1 – Primers sequences used for QPCR.

| Gene      | Forward (5’ → 3’) | Reverse (5’ → 3’) |
|-----------|-------------------|-------------------|
| Acta2     | CTGACAGAGGGACACGAGTGAAG | CACCTCAGAGCATCGGAGACCA |
| b-actin   | AGATGTGCTGAGTCAACGAGGC | GGGCAGTGGATGACTGAGAAG |
| Cidea     | TGACTTCTGGAAATGATGACGC | GGGCAGTGGATGACTGAGAAG |
| Col1a1    | AGAGCGGAGGATGAGTGAGGA | AGAGCGGAGGATGAGTGAGGA |
| Col1a2    | CTGACAGAGGGACACGAGTGAAG | CACCTCAGAGCATCGGAGACCA |
| Col1a4    | TTTCTGGATTCCCTGGACTGAC | GTCTCAGTTCTCTCTGTCCTG |
| Col1a6    | CTGCTCTGAAGGAGGTGGAA | GTCTCAGTTCTCTCTGTCCTG |
| F4/80     | CTTGCTGATGCTCCTGGTCTGAC | GTCTCAGTTCTCTCTGTCCTG |
| Gapdh     | AGTCGCTGGAGACGAGTGGTT | GTGACTGATTCTGAGGTTGCA |
| Hprt      | TGGAGCGGAGGATGAGTGAGGA | AGAGCGGAGGATGAGTGAGGA |
| Itb       | AAATTCCGCTGCTGGTGGAC | CGGCTGATGACGAGAGTTTAC |
| R6        | CTGCAATGACCTGCTGGTGGAC | AGAGCGGAGGATGAGTGAGGA |
| t10       | AAGCCAGGAGGATGAGTGAGGA | AGAGCGGAGGATGAGTGAGGA |
| IVOS      | GAGGCCAGGAGAGGAGGATGCG | TCTCAGGACGAGCTCTGGTGGT |
| Lox       | CAGCAGGATCACTGCTGGTGGAC | CGGCTGATGACGAGAGTTTAC |
| Mmp1      | CACATCAGCTCGCTGGTGGTAC | TGGAGCGGAGGATGAGTGAGGA |
| Mmp3      | ACATGAGACTTTCCTGGTCTGAT | TGGAGCGGAGGATGAGTGAGGA |
| Mmp9      | GCCGTCGCTCAGCCGACTTAC | GACCCGACCTGCTGGTCC |
| Mmp13     | TCTCCCTTGATGACCTGCTCAG | TGGAGCGGAGGATGAGTGAGGA |
| Pgc1a     | CAAGCTGCTCAGCCGATGAC | CGGCTGATGACGAGAGTTTAC |
| Ppara     | TACGGCTGCTCAGCCGATGAC | CGGCTGATGACGAGAGTTTAC |
| Prdm16    | CCACGAGCCGACTCCGATC | GACCCGACCTGCTGGTCC |
| Taz       | GGCTGGCAAGAATGCTGAA | AGACTCAGTCTCCGGACG |
| Tgfb      | AACGCTGCTCAGCCGACTTAC | GACCCGACCTGCTGGTCC |
| Tenf      | CTGCAATGACCTGCTGGTGGAC | AGAGCGGAGGATGAGTGAGGA |
| Tmem26    | GACCGACTCAGCTGACGAC | AGAGCGGAGGATGAGTGAGGA |
| Ucp1      | GTGAAAGCTGCAATGCGAG | AGAGCGGAGGATGAGTGAGGA |
| Yap       | AGACGACGAGGATGAGTGAGGA | AGAGCGGAGGATGAGTGAGGA |

### 2. METHODS

#### 2.1. Animals

Adiponectin-Cre+ mice (Jackson Laboratory, Bar Harbor, ME, USA) were crossed with YAP knockout mice generated from Taz fox/Yap fox mice, a gift from Jeff Wrana (Mount Sinai Hospital, Toronto, ON, Canada), to generate AdipoqCre+ YAP+/− mice [19,20]. These mice were then intercrossed to generate mice with adipocyte-specific deletion of YAP (AdipoqCre+ YAP−/−) and maintained on a C57Bl/6 background [21,22]. Littermate AdipoqCre+ YAP−/− mice were used as controls. Genotypes were typed by PCR using DNA from an ear notch. Prior to weaning, ear clips were obtained from 12 to 14-day-old pups and digested using the REDExtract-N-Amp Tissue™ Kit (Sigma—Aldrich, St. Louis, MO, USA). All primers used for mouse genotyping were purchased from Integrated DNA Technologies, Skokie, IL, USA. For Cre genotyping, the forward 5’-GCC AGT AAA AAC TAT CCA GCA A-3’ and reverse 5’-GGT ATA AGC AAT CAC TCT CCA G-3’ primers were used. For YAP genotyping, the forward 5’-AAG ACA CTT CAC TCT GAC TCC-3’ and reverse 5’-GAA TAT CCA TCC CAG ACG ACC-3’ primers were used. The following program was used for the PCR: the melting temperature was 94 °C for 4 min, the annealing temperature was 60 °C for 30 s, and the primer extension phase was 72 °C for 30 s for 35 cycles. The final PCR product is 204 bp for the wild type allele and 287 bp for the mutant allele.

Mice were housed in a pathogen-free animal facility with a 12-hour light–dark cycle and fed with standard commercial chow diet ad libitum (5% fat; HarlanTeklad). Starting at 6 weeks of age, mice were randomly assigned to be fed with either HFD (60% fat, 24% carbohydrates, and 16% protein based on caloric content; F3282; BioServ, Flemington, NJ, USA) or standard chow diet for 12 weeks. Animals were excluded from the study if injured or sick, which occurred with similar rates in both knockout and control animals (1–2%). Male mice were used where not otherwise specified. All experimental procedures were approved by the Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute Animal Care Committee.

#### 2.2. In vivo metabolic studies

Glucose tolerance tests were performed after fasting the mice overnight (12–16 h), injecting 1 g of glucose per kg of body weight intraperitoneally. Insulin tolerance tests were performed after fasting the mice for 4 h, injecting insulin lispro (Eli Lilly, Indianapolis, IN, USA) 1.0 U per kg of body weight intraperitoneally. Blood glucose measurements were taken at 0, 15, 30, 45, 60, and 120 min after injection using a Contour glucometer (Ascensia Diabetes Care, Parsippany, NJ, USA) [23]. For energy expenditure measurements, mice were individually housed in metabolic cages with free access to water and food. After 24-hour acclimatization period, data for 24 h were collected and analyzed using the Comprehensive Lab Animal Monitoring System (Columbus Instruments, Columbus, OH, USA).

#### 2.3. Adipocyte isolation

Mouse fat pads were removed and thoroughly minced using a razor blade. Minced cells were added to 1 mg/mL of Type I collagenase (Worthington Biochemical, Lakewood, NJ, USA) solution prepared in KRBH buffer. The solution was then incubated at 37 °C and vortexed every 5 min. Cell suspension was centrifuged at 2200 rpm for 10 min and the adipocyte fraction was collected from the supernatant [21]. Total protein extract from cultured human adipocytes was obtained.
from Zen-Bio (Durham, NC, USA). Samples were from healthy women with or without diabetes (n = 3; average BMI 39.5; range 26.1–52.1; average age 38; range 37–40 for people without diabetes and n = 3; average BMI 46.8; range 39.5–57.4; average age 43; range 40–47 for people with type 2 diabetes). Subjects with or without obesity and type 2 diabetes who were scheduled for a laparoscopic gastric banding surgical procedure were recruited to provide adipose tissue. Consent was obtained and procedures conducted in accordance with protocols approved by the University and Medical Center Institutional Review Board, East Carolina University, Greenville, NC, USA.

2.4. Cell culture
3T3-L1 preadipocytes were cultured and differentiated as per manufacturer protocol (ZenBio, Durham, NC, USA). Cells were maintained at 37 °C with 5% CO2 and the media was changed every 2–3 days. For YAP inhibition, 3T3-L1 mature adipocytes were treated with the drug verteporfin (VP; Tocris Bioscience, Bristol, UK). After 10 days of differentiation, cells were treated with 1.25 μM of VP diluted in dimethyl sulfoxide (DMSO). After a 24-hrs treatment period, cells were washed with sterile 10% phosphate buffered saline (PBS; pH 7.4) and lysates were collected for subsequent analyses.

For TGFβ stimulation, 3T3-L1 mature adipocytes were treated with a recombinant TGFβ1 (Bón Opus Biosciences, Millburn, NJ, USA). After 10 days of differentiation, 10 ng/mL of TGFβ1 was added to cells for 24 h. Cells were washed and lysates were collected following incubation for subsequent analyses. To inhibit YAP and stimulate TGFβ signaling simultaneously, 3T3-L1 mature adipocytes were treated with both VP and recombinant TGFβ1 for 24 h.

For YAP knockdown, 3T3-L1 preadipocytes were grown to 70% confluence then treated with Silencer Select Negative Control siRNA (4390843, Ambion) or Silencer Select siRNA for YAP (s20366, Ambion) with Lipofectamine RNAiMAX Transfection Reagent (13778100, Thermo Fisher Scientific) according to the manufacturer’s protocol. After 7 days of differentiation, for TGFβ stimulation, 10 ng/mL of TGFβ1 was added to specified adipocytes for 24 h. Cells were washed with PBS and lysates were collected for analyses.

2.5. Immunoblotting
Protein lysates were obtained for Western blots by first crushing the tissues in liquid nitrogen. Cold lysis buffer consisting of RIPA buffer and a protease inhibitor cocktail (sc-24948A; Santa Cruz Biotechnology, Dallas, TX, USA) was then added to the crushed tissues to mechanically homogenize using the ultrasonic processors (Betatek, Toronto, ON, Canada). Protein concentrations were then measured using the Bradford protein assay (Sigma–Aldrich, St. Louis, MO, USA) with a microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). After determination of the protein concentrations, 30 μg of total protein was combined with Laemmli sample buffer (Bio-Rad Laboratories, CA, USA) and boiled for 5 min at 95 °C for loading. Protein samples were then run on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in a running buffer solution (5 mM Tris base, 192 mM glycine, and 0.1% SDS). Proteins were transferred onto a methanol-hydrated polyvinylidene difluoride (PVDF) membrane. To block non-specific protein binding, membranes were incubated in 5% non-fat dry milk in Tris-buffered saline solution containing 0.1% Tween-20 (TBST, 20 mM Tris-Cl, 136 mM NaCl, and 0.1% Tween-20) for 1 h at room temperature. Membranes were then washed three times with TBST for 15 min. Membranes were incubated overnight at 4 °C with primary antibodies (YAP: 1:1000 dilution; sc-101199; Santa Cruz Biotechnology, Dallas, TX, USA), phospho-YAP (p-YAP) (1:1000 dilution; D9W2I; Cell Signaling Technology, Danvers, MA, USA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:10,000 dilution; 14C10; Cell Signaling Technology, Danvers, MA, USA), and β-actin (1:5000 dilutions; A1978; Sigma–Aldrich). After overnight incubation, membranes were washed three times with TBST for 15 min, then incubated in secondary HRP-conjugated polyclonal goat anti-mouse antibody (1:5000 dilution; ab6789) or HRP-conjugated polyclonal goat anti-rabbit antibody (1:5000 dilution; ab6721) in 5% non-fat dry milk diluted in TBST for 1 h at room temperature. All secondary antibodies were purchased from Abcam (Cambridge, UK). Membranes were washed three times with TBST for 15 min. Membranes were then incubated with Amersham™ ECL Prime Western Blotting detection reagent (GE Healthcare UK, Buckinghamshire, UK) at room temperature to expose the membranes and imaged using ChemiDoc™ Touch Imaging System (Bio-Rad Laboratories). Protein band intensities were quantified using Fiji software (Schindelin et al., 2012).

2.6. RNA isolation and quantitative real-time PCR
Adipocyte RNA was isolated by following the modified steps from the routine RNeasy Plus Universal Mini Kit protocol (Qiagen, Hilden, Germany) [24]. RNA was reverse transcribed by random primers and quantitative reverse transcription PCR was performed with SYBR Green master mix reagent (Applied Biosystems, Foster City, CA, USA). Primer sequences are listed in Table 1. Data analysis was performed using the comparative Ct method.

2.7. Histology
Mouse fat pads were isolated and fixed in 4% paraformaldehyde. Sections were then stained with haematoxylin and eosin. Adipocyte size and quantity were measured using Fiji software [25]. For immunofluorescence staining, sections were permeabilized with PBST for 20 min then blocked using DAKO Protein Block Serum-Free (Agilent X0909) for an hour. Sections were then stained with anti-YAP IgG (Cell Signaling #14074) at 1:100 dilution overnight at 4 °C. Alexa Fluor 647 conjugated anti-rabbit IgG (Thermofisher Catalog # A-21245) at 1:300 dilution was applied for 1 h at room temperature followed by Alexa Fluor 555 conjugated anti-periilpin IgG (Thermofisher Catalog # PA1-1051-A555) at 1:100 dilution for 1 h at room temperature. DAPI (Thermofisher Catalog # 62248) at 1:1000 dilution was then applied for 10 min and sections subsequently mounted with DAKO Fluorescent mounting media (Agilent GM304). Three 5-min washes with PBS were done between each staining step and before mounting. Images were taken with a ZEISS Axio Scan.Z1 Slide Scanner and nuclear localization quantified using ImageJ.

2.8. Human adipocyte transcriptomics data analysis
Pre-normalized (Transcript per Million, TPM) bulk RNA sequencing data of 454 periumbilical subcutaneous adipose tissue biopsies were obtained from Gene Expression Omnibus (GEO) accession GSE135134 [26]. TPM expression values for each were correlated with patient BMI, and correlation Rho coefficients were used in Gene Set Enrichment Analysis (GSEA-Preranked), performed using GSEA software version 4.1.0 (Broad Institute, Cambridge, MA, USA) [27,28]. Raw count bulk RNA sequencing data of superficial subcutaneous adipose tissue biopsies from 6 healthy patients and 6 patients with obesity and type 2 diabetes mellitus were obtained from GEO accession GSE104674 [29]. Values were normalized using DESeq2 [29], and further pre-processed using the natural log of 1 + normalized counts (log1p). Gene set variation analysis (GSEA) was performed on fully normalized data in R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) using GSVA package version 1.34.0 (using
Figure 1: Yap protein is increased in adipose tissue with obesity and insulin resistance. (A) Immunoblot showing YAP protein in omental adipocytes from humans with and without type 2 diabetes (n = 3 per group). Representative sample from a person without and a person with diabetes is shown, with quantification including all samples. (B) Immunoblot of YAP in inguinal, perigonadal, and interscapular brown adipose tissue of mice on high fat diet (HFD) and chow diet, with GAPDH as a loading control (n = 4 per group). Representative samples and quantification of all samples are shown. (C) Immunofluorescence staining and quantification of YAP (green), perilipin (red), and DAPI (blue) in perigonadal adipose tissue of control mice fed with 12 weeks of chow diet and high-fat diet (n = 3–5 per group). Arrows indicate nuclear localization of YAP. (D) Enrichment plot of YAP transcriptional targets among BMI correlated genes. (E) YAP transcriptional activity in healthy and obese individuals with type 2 diabetes at different Zeitgeber Times. iWAT, inguinal white adipose tissue; pWAT, perigonadal white adipose tissue; iBAT, interscapular brown adipose tissue. Data are mean ± SEM. *p < 0.05 and **p < 0.01 by Student’s t-test (A, B, C) and two-way ANOVA with Bonferroni’s test (E).
percentage of adipocytes with nuclear localization of YAP (Figure 1C). In addition to examining YAP levels, we performed immuno

3. RESULTS

3.1. YAP protein is increased in adipose tissue with obesity and insulin resistance

To explore the role of YAP in adipose tissue and glucose homeostasis, we first examined levels of YAP protein in humans and mouse models of insulin resistance. Data from publicly available datasets searchable on BioGPS (http://biogps.org) suggest that white adipose tissue is a significant site of YAP and TAZ expression in both humans and mice. We also found that YAP was robustly present in omental adipocytes from humans, as well as inguinal white adipose tissue (iWAT), perigonadal white adipose tissue (pWAT), and interscapular brown adipose tissue (iBAT) from mice (Figure 1A, B, Supplementary Fig. 1). Furthermore, YAP was increased in omental adipocytes from humans with type 2 diabetes compared to humans without diabetes (Figure 1A). We saw similar results in a mouse model of diet-induced obesity and insulin resistance. YAP protein levels were increased in iWAT, pWAT, and iBAT from mice fed a HFD for 12 weeks (Figure 1B). In this setting, YAP phosphorylation also appeared decreased in iWAT but not consistently different in pWAT (Supplementary Figs. 2A-C). An increase in YAP was more prominent in adipose tissue compared to other glucoregulatory tissues examined, such as liver and muscle (Supplementary Figs. 3A–C). In addition to examining YAP levels, we performed immunofluorescence staining to examine intracellular YAP localization. In the setting of metabolic stress, we saw an increased percentage of adipocytes with nuclear localization of YAP (Figure 1C). We also looked at whether there is an increase in YAP transcriptional signature in adipocytes from patients with diabetes or metabolic syndrome versus healthy individuals. Using publicly available adipocyte transcriptomics data, we reviewed and analyzed for changes in adipocyte YAP transcriptional activity in the setting of obesity, insulin resistance, and diabetes. A study by Raulerson et al. used participants from the METabolic Syndrome in Men (METSIM) study, which is a population-based cohort study of 10,197 males of Finnish ancestry in Finland [26]. A subset of 550 patients from METSIM who underwent periumbilical subcutaneous adipose tissue biopsies were used in the study. A total of 434 patients were included in the final data analysis. BMI data was available for each patient. We performed Gene Set Enrichment Analysis (GSEA), which compares enrichment of a group of genes between groups of samples or patients. This generated a p-value and an enrichment score for each group of patients compared. GSEA demonstrated a significant enrichment of YAP transcriptional targets among BMI-correlated genes in this cohort (p-value <0.001) (Figure 1D). Another study by Stenvers et al. recruited six obese individuals with type 2 diabetes and six healthy control patients [29]. Superficial subcutaneous adipose tissue samples were obtained by needle aspirations at various individual zeitgeber time (ZT) to study the difference between obese individuals with type 2 diabetes and healthy lean control individuals in the diurnal rhythms of the subcutaneous adipose tissue transcriptome. We found that YAP transcriptional activity was significantly increased in obese individuals with type 2 diabetes compared to healthy control individuals at all four ZTs (Figure 1E). Collectively, these data suggest that YAP protein level, nuclear localization and transcriptional activity increases in adipocytes with metabolic disease, implicating that YAP may play a role in the context of adipose tissue expansion and insulin resistance.

3.2. Generation of adipocyte-specific YAP knockout mice

To further study the role of YAP specifically in adipose tissue and in whole body metabolism, we generated novel adipocyte-specific YAP knockout mice using a Cre-loxP recombination system. We bred adiponectin-Cre mice expressing Cre recombinase specifically in adipocytes to mice with loxp sites flanking exon 2 of the Yap1 gene to generate AdipoqYAPfl/−/− mice (Figure 2A) [19,20]. Genotypes of experimental mice were confirmed by PCR (Figure 2B). Both YAP protein and gene expression were significantly decreased in the major adipose depots of inguinal and perigonadal fat compared to littermate controls, consistent with other reports using adiponectin-Cre systems (Figure 2C,D, Supplementary Fig. 4)[21,22,32,33]. We also measured the expression of TAZ, a YAP paralog, in our knockout model to identify any compensatory changes. There was no difference in the relative expression of Taz between AdipoqYAPfl/−/− controls and AdipoqYAPfl/+ mice (Figure 2E). Adipocyte-specific YAP knockout mice and littermate AdipoqYAPfl/+ controls appeared healthy and normal. There was no difference in total body weight between knockout and control animals when fed either a Chow diet (Figure 2F) or HFD (Figure 2G, Supplementary Fig. 5A).

3.3. Adipocyte-specific disruption of YAP improves glucose tolerance

To identify whether adipocyte YAP plays a role in glucose homeostasis, we measured random and fasting blood glucose levels in Chow and HFD-fed AdipoqYAPfl/−/− and littermate AdipoqYAPfl/+ control mice. By 12 weeks of age, male AdipoqYAPfl/−/− mice on regular Chow diet had lower fasting blood glucose levels (Figure 3A). No difference in random blood glucose was seen likely due to greater variability in the fed state (Figure 3B). In the setting of metabolic stress induced by HFD, by 12 weeks of age male AdipoqYAPfl/−/− mice had lower fasting blood glucose levels (Figure 3A). No difference in random blood glucose was seen likely due to greater variability in the fed state (Figure 3B). In the setting of metabolic stress induced by HFD, by 12 weeks of age male AdipoqYAPfl/−/− mice had lower fasting blood glucose levels (Figure 3A) and by 14 weeks of age male AdipoqYAPfl/−/− mice also had lower random blood glucose (Figure 3D). With 12 weeks of HFD, female mice did not gain as much weight as male mice, and no difference in fasting blood glucose was seen in this group (Supplementary Figs. 5A and B). On further testing, male HFD-fed AdipoqYAPfl/−/− mice had improved glucose tolerance with lower blood glucose levels on glucose tolerance testing (GTT) compared to littermate controls (Figure 3F). No difference was seen at baseline in Chow diet-fed mice or in female HFD-fed mice (Figure 3E, Supplementary Fig. 5C). No difference was seen in insulin tolerance testing (ITT) in either males or females (Figure 3G, H, Supplementary Fig. 5D). This suggests that YAP plays an important role in adipocytes and regulation of glucose tolerance, particularly in the setting of diet-induced weight gain.
3.4. Knockdown of YAP in adipose tissue decreases perigonadal fat weight in vivo

YAP-mediated signaling can regulate tissue size and dual YAP and TAZ deletion results in decreased adiposity. To determine whether adipocyte YAP alone may regulate adiposity in vivo, we assessed body composition by weighing key fat pads in mice fed chow and HFD. Under basal conditions with chow diet, there was no difference in the perigonadal fat pad weight between AdipoqYAP+/−/C0 mice and controls (Figure 4A). In the HFD-fed setting, perigonadal fat pad weight was decreased in AdipoqYAP+/−/C0 mice compared to controls (Figure 4B). This was associated with a larger number of smaller adipocytes in knockout mice compared to littermate controls (Figure 4F). No difference in circulating triglyceride or cholesterol levels were seen between groups (Figure 4G). Overall, this demonstrates that YAP regulates fat pad size in vivo via determination of adipocyte size and number in the setting of nutrient excess.

3.5. Deletion of YAP does not alter regulation of whole-body energy homeostasis

Because of the lower adiposity seen in AdipoqYAP+/− mice, we then sought to determine whether adipocyte YAP also regulates whole body energy expenditure. We measured metabolic parameters in individually housed AdipoqYAP+/− and littermate control mice. There was no significant difference in energy expenditure, as measured by oxygen consumption in mice (Figure 5A). There was no overall difference in...
fuel utilization measured by respiratory exchange ratio (Figure 5B). Body temperature and locomotor activity were also not significantly different (Figure 5C, D). Food intake and water intake were also similar between the two groups (Figure 5E, F). Overall, this suggests a role for YAP in determining adipocyte size and glucose homeostasis that does not significantly alter whole body energy expenditure.

3.6. Adipocyte-specific deletion of YAP decreases inflammation and protects against adipose tissue fibrosis

In the setting of obesity, adipose tissue undergoes pathological remodeling, and this can initiate an inflammatory response, characterized by infiltration of proinflammatory macrophages and increased fibrosis. This increased inflammation and fibrosis in adipose tissue is associated with metabolic complications such as insulin resistance. To see whether adipocyte YAP regulates inflammation in the setting of nutrient excess, we measured the gene expression of key proinflammatory markers in adipose tissue from AdipoqYAP−/− and littermate control mice fed with HFD for 20 weeks. We found that the expression of key proinflammatory cytokines in perigonadal fat from AdipoqYAP−/− mice was significantly decreased compared to controls (Figure 6A). This was consistent with lower mRNA expression of Emr1 and a lower number of crown-like structures (CLSs) as measured by F4/80 immunohistochemical staining in perigonadal fat from AdipoqYAP−/− compared to AdipoqYAP+/+ mice (Figure 6B–D). Emerging data suggest that YAP plays an important role in regulating the development of lung, liver, kidney, and heart fibrosis. However, whether YAP plays a similar role in adipose tissue remains unknown. To gain a better understanding of the role of YAP in the pathophysiology of adipose tissue fibrosis, we measured the expression of key profibrotic genes in AdipoqYAP−/− and littermate control mice. Under
Figure 4: Adiposity is decreased in adipocyte-specific YAP KO mice. (A,B) Weight of tissues at 14 weeks of chow diet (A) and 12 weeks of HFD (B) in AdipoqYAP<sup>+</sup>/+ and AdipoqYAP<sup>−/−</sup> mice (n = 8–10 per group). (C) Hematoxylin and eosin staining in perigonadal white adipose tissue from AdipoqYAP<sup>+</sup>/+ and AdipoqYAP<sup>−/−</sup> mice fed HFD for 12 weeks. (D) Adipocyte size distribution, (E) average adipocyte diameter, and (F) calculated total adipocyte number in perigonadal white adipose tissue of AdipoqYAP<sup>+</sup>/+ and AdipoqYAP<sup>−/−</sup> mice fed with HFD for 12 weeks (n = 3 mice per group). (G) Triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol levels in AdipoqYAP<sup>+</sup>/+ and AdipoqYAP<sup>−/−</sup> mice fed HFD for 12 weeks. Data are mean ± SEM. *p < 0.05 and **p < 0.01 by Student’s t-test.
HFD-fed setting, we saw a significant reduction in Col1a1, Col3a1, Col6a1, and Tgfβ1 in the perigonadal fat from AdipoqYAP+/YAP/C0/C0 mice compared to controls (Figure 6E). Furthermore, excess collagen deposition, a characteristic of adipose tissue fibrosis, was seen to a lesser degree as shown by picrosirius red (PSR) staining in perigonadal fat pads from HFD-fed AdipoqYAP+/YAP/C0/C0 mice (Figure 6F, G). Overall, this demonstrates that disruption of YAP resulted in decreased inflammation and protected against adipose tissue fibrosis in the setting of metabolic stress induced by HFD.

3.7. Direct inhibition of adipocyte YAP decreases genes involved in fibrosis signaling

Based on our in vivo data and given the central role of YAP in fibrosis, we examined whether YAP directly affects profibrotic gene expression in adipocytes. To address this question, we pharmacologically depleted YAP in differentiated 3T3-L1 adipocytes. Specifically, we administered a drug called verteporfin (VP), which is used to treat patients with macular degeneration. Consistent with previously described inhibitory effects of VP on YAP [12], we found that 3T3-L1 mature adipocytes treated with VP had decreased YAP protein levels compared to cells treated with DMSO (Figure 7A). In addition, targeting YAP using VP led to decreased YAP mRNA levels compared to DMSO-treated controls (Figure 7B). Additionally, we were able to knockdown YAP with siRNA transfection in 3T3-L1 adipocytes, with significantly decreased YAP protein and mRNA expression levels (Supplementary Figs. 6A and B).

Among the different mediators involved in tissue fibrosis, TGFβ1 is considered a key molecule in the activation of fibrosis signaling. To induce fibrosis in vitro and assess the impact of TGFβ1 on adipocytes, we incubated 3T3-L1 mature adipocytes with recombinant TGFβ1 protein. As previously described, YAP levels were several-fold higher in adipocytes treated with TGFβ1 compared to controls (Figure 7B). We then examined the effect of VP on YAP in the presence of TGFβ1. Simultaneous VP and TGFβ1 treatment decreased YAP gene expression to levels similar to baseline (Figure 7B). Because TAZ is a paralog of YAP, we investigated whether VP exerts a similar inhibitory effect on TAZ in adipocytes. Intriguingly, TAZ expression was not significantly reduced in 3T3-L1 adipocytes treated with VP (Figure 7C). While TGFβ1 treatment enhanced TAZ expression compared to controls (Figure 7C), we also find that treatment with VP and TGFβ1 did not reduce TAZ levels (Figure 7C).

To assess the impact of VP treatment on fibrosis, qPCR analysis of key profibrotic genes was performed. We first measured TGFβ1 levels in the three treatment groups. As expected, VP treatment significantly reduced Tgfβ1 expression while recombinant TGFβ1 treatment increased Tgfβ1 expression by more than 8-fold compared to cells treated with DMSO (Figure 7D). When VP and TGFβ1 treatment was combined, TGFβ1 expression was only increased by approximately...
1.5-fold (Figure 7D). Next, we measured the expression of key collagens involved in ECM. As shown in Figure 7E, collagen expression is significantly reduced with VP treatment. In contrast, these collagen levels are approximately 4-fold higher in the TGF-β1 treatment group compared to controls (Figure 7E). However, this increase was no longer present when VP was combined with TGF-β1 (Figure 7E).

To further assess the impact of reduced YAP on fibrosis, we measured the expression of additional markers of fibrosis. As expected, VP treatment significantly reduced the mRNA levels of *Acta2* and *Lox*, while TGF-β1 treatment increased their expression, and simultaneous VP and TGF-β1 resulted in a smaller increase (Figure 7F). A similar trend in Lox expression was seen with siRNA knockdown of YAP (Supplementary Fig. 6C). Next, we measured the expression of MMP-3, -9, and -13, which play an important role in regulating matrix integrity and stability. Treatment of mature 3T3-L1 adipocytes with VP to inhibit YAP reduced MMP-3, -9, and -13 expressions compared to controls (Figure 7K). These MMPs increased two-fold in adipocytes treated with TGF-β1 but not when adipocytes were simultaneously treated with VP (Figure 7K). These results suggest that YAP disruption in adipocytes directly reduces expression of fibrosis genes. Overall, this identifies a new role specifically for YAP in adipose tissue inflammation, fibrosis, and glucose metabolism.

### 4. DISCUSSION

There is a growing need to understand the factors determining adipocyte function in the highly dynamic setting of nutrient excess and metabolic disease. The Hippo signaling pathway is a key player...
in tissue growth and increasingly recognized for a role in fibrosis. Here, we found that in both humans and mouse models with insulin resistance, YAP is increased in adipocytes. Deletion of adipocyte YAP decreased fasting blood glucose levels and decreased perigonadal fat mass in male mice fed HFD. These findings occurred in the absence of a significant difference in whole body weight, inguinal fat pad weight, interscapular fat pad weight, or energy expenditure. Furthermore, deletion of adipocyte YAP decreased adipose tissue inflammation and fibrosis. These findings suggest that YAP plays an important role in adipocyte determination of whole-body glucose tolerance and protects against HFD-induced inflammation and fibrosis.

A growing number of studies propose a key role for Hippo signaling in adipose tissue. Upon activation, the extracellular signals are transduced to kinases MST1/2, which are associated with tumor suppressor protein Salvador to form an active enzyme complex [10]. This complex phosphorylates and activates large tumor suppressors 1/2 (LATS1/2), which are two kinases that are regulated by Mob1A/1B subunits. Following the activation of LATS1/2, YAP/TAZ are phosphorylated and inactivated, leading to their accumulation in the cytoplasm and degradation through recruitment of the SCFβ-TrCP E3 ubiquitin ligase [34–36]. Retention of YAP/TAZ in the cytoplasm inhibits the expression of target genes responsible for cell survival. Conversely, active YAP/TAZ are dephosphorylated and translocated to the nucleus, where it associates with TEA domain (TEAD) family transcription factors to activate the expression of TEAD target genes, including Myc, amphiregulin, Wnts, and connective tissue growth factor (CTGF) [37–39]. Our data suggest that increased YAP levels and YAP nuclear localization in the setting of obesity-associated insulin resistance could contribute to increased activation of gene transcription.

Complementary to our work, previous studies have focused on regulation of adipogenesis, primarily in vitro. TAZ has been implicated in repressing the major adipogenic transcription factor PPARγ in mesenchymal stem cells [16]. Similarly, in 3T3-L1 mature adipocytes, LATS2 was found to phosphorylate YAP and TAZ, decreasing activation of transcription factor TEAD and downstream adipogenic gene transcription [15]. In one model of YAP overexpression, TAZ down-regulation was thought to promote adipogenesis [40]. Finally,

Figure 7: Verteporfin treatment decreases the expression of key profibrotic genes in 3T3-L1 adipocytes. (A) Immunoblot of YAP in differentiated 3T3-L1 adipocytes treated with control (C), DMSO (D), and verteporfin (VP), with GAPDH as a loading control. (B) Relative expressions of Yap and (C) Taz mRNA in DMSO, VP, TGFβ1, and VP + TGFβ1 treated cells. (D–M) Relative mRNA expressions of profibrotic genes in DMSO, VP, TGFβ1, and VP + TGFβ1 treated cells. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way ANOVA with Fischer’s LSD test.
disruption of TAZ in adipocytes was recently shown to increase PPARγ activity to decrease adipose tissue inflammation, improve insulin sensitivity, and glucose tolerance [17]. Collectively, this suggests that adipogenesis via PPARγ activity could potentially be regulated by Hippo signaling. However, further investigation is needed to determine the role of YAP in this context. Despite these emerging studies on TAZ, the specific role of its paralog YAP is less well known. Studies in vitro in some cell types suggest that similar to TAZ, YAP could regulate adipogenesis. YAP knockdown suppresses differentiation in ovine preadipocytes and rat adipose-derived stem cells [41,42]. Furthermore, a recent study has shown that YAP/TAZ are activated by the proinflammatory cytokines in both human and mouse mature adipocytes to promote adipocyte survival during WAT expansion [18]. Wang et al. further showed that YAP/TAZ regulate the balance between adipocyte death and the formation of new adipocytes in the setting of obesity [18]. However, the specific role of YAP in mature adipocytes and in vivo, particularly with metabolic dysfunction is not known. Our objective was to study the role of YAP in mature adipocytes, in whole body physiology and in the setting of obesity-associated metabolic dysregulation. While others have described that the expression of YAP is less than TAZ in adipose tissue under basal conditions [17], here we found that YAP increases, with increased nuclear localization in adipocytes in the setting of obesity and insulin resistance. Furthermore, we found that YAP transcriptional activity is increased in humans with obesity and type 2 diabetes, suggesting a potentially important role of YAP in gene regulation in the setting of metabolic dysfunction.

The rapid remodeling of adipose tissue is due to the coordinated response of resident adipose tissue cells, including adipocytes, macrophages, endothelial cells, and fibroblasts [43]. With excess nutrient availability, adipocytes increase lipid storage and expand in size. Under normal physiological conditions, adipose tissue mobilizes the surplus of lipids and maintains energy homeostasis during nutrient deprivation [44]. With obesity and insulin resistance, there is increased lipolysis resulting in excess circulating levels of free fatty acids derived from triacylglycerides [45]. This can activate proinflammatory pathways and impair insulin signaling. Consequently, obesity-associated insulin resistance is associated with increased inflammation and macrophage infiltration. We found that AdipoqYAP−/− mice fed with HFD had more and smaller adipocytes. While this could not be accounted for by differences in triglyceride levels, AdipoqYAP−/− mice had less adipose tissue macrophage accumulation and lower expression of proinflammatory and collagen genes compared to littermate controls, consistent with decreased inflammation associated with improved glucose homeostasis.

Adipose tissue inflammation and dysglycemia has been associated with increased fibrosis formation, ultimately leading to metabolically dysfunctional adipose tissue. Several studies have shown that YAP plays an important role in the development of lung, liver, and kidney fibrosis [12–14]. However, the role of YAP in the context of adipose tissue fibrosis is unknown. In the current study, we demonstrated that knocking out YAP in adipocytes reduces the expression of profibrotic genes and decreases collagen deposition in perigonadal white adipose tissue. Our findings suggest that deleting YAP in adipocytes reduces the development of fibrosis in the setting of diet-induced obesity.

Given the important role of YAP in the pathogenesis of fibrosis, we examined whether YAP directly affects adipocytes to regulate fibrosis. To address this question, we inhibited YAP in 3T3-L1 mature adipocytes using a drug called VP and knocked down YAP with siRNA transfection, then measured key profibrotic genes under different settings. Several studies have shown that VP inhibits YAP by disrupting the YAP-TEAD complex [46–48]. Consistent with this finding, we show that 3T3-L1 adipocytes treated with VP decreased YAP protein levels. To induce fibrosis in vitro, we treated differentiated 3T3-L1 adipocytes with recombinant TGFβ1. We showed treatment with TGFβ1 led to upregulation of key profibrotic genes in adipocytes. To determine whether pharmacological or genetic inhibition of YAP could reverse TGFβ1-induced fibrosis, we treated the cells with VP or siRNA and TGFβ1 simultaneously. Key profibrotic genes, such as Lox, were reduced upon treatment with both VP or siRNA and TGFβ1. This data confirms a direct role of YAP in regulating fibrotic gene expression in adipocytes.

Limitations of this study include its focus on fibrosis. Adipocytes are capable of multiple homeostatic roles, and YAP may have diverse, context-specific functions. Further work is needed to determine whether acute inhibition of knockdown of YAP in vivo may inhibit fibrosis and ultimately improve glucose homeostasis.

Overall, this study identifies a key novel role for YAP in adipocytes, particularly in the setting of obesity-associated insulin resistance. YAP protein increases in adipose tissue in this setting and deletion of YAP results in decreased adiposity and improved glucose tolerance with diet-induced obesity, potentially via decreases in adipose tissue inflammation and fibrosis. This study improves our understanding of adipose tissue regulation in a model of type 2 diabetes.

**AUTHOR CONTRIBUTIONS**

DJH, HS, DAY and CTL designed and oversaw the study. DJH, RA, TO, PSM, FC, and CKC conducted experiments and analyzed data. DJH, CTL and AC drafted and revised the manuscript. All authors have reviewed the manuscript.

**FINANCIAL SUPPORT**

This work was supported by a Natural Sciences and Engineering Research Council of Canada discovery grant RGPIN-2018-05671, J.P. Bickell Foundation grant, Banting and Best Diabetes Centre Gales Family Charitable Foundation pilot and feasibility grant, Heart and Stroke Richard Lewar Centres of Excellence in Cardiovascular Research (HSRCLC) and Bi-LILLY new investigator award, Canadian Institutes of Health Research project grant PJT-168996 and CIHR early career investigator award ARI-170743. DJH was supported by a BBDC-Novo Nordisk graduate studentship and Ontario Graduate Scholarship (OGS). DAY was supported by a CIHR New Investigator Award. CTL was supported by a Heart and Stroke Heart and Stroke Canada (HSFC) new investigator award.

**CONFLICT OF INTEREST**

None declared.

**DATA AVAILABILITY**

Data will be made available on request.

**APPENDIX A. SUPPLEMENTARY DATA**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2022.101594.
and is required for diet- and cold-induced thermogenesis in mice. Diabetologia 59(1):187–196. https://doi.org/10.1007/s00125-015-3786-2.

[33] Shi, S.Y., Luk, C.T., Brunt, J.J., Sethuraman, T., Lu, S.Y., Schroer, S.A., et al., 2014. Adipocyte-specific deficiency of Janus kinase (JAK) 2 in mice impairs lipolysis and increases body weight, and leads to insulin resistance with ageing. Diabetologia 57(5):1016–1026. https://doi.org/10.1007/s00125-014-3186-0.

[34] Liu, C.Y., Zha, Z.Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., et al., 2010. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. Journal of Biological Chemistry 285(48):37159–37169. https://doi.org/10.1074/jbc.M110.152942.

[35] Zhao, B., Li, L., Tumaneng, K., Wang, C.Y., Guan, K.L., 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP. Genes & Development 24(1):72–85. https://doi.org/10.1101/gad.1602907.

[36] Zhao, B., Wei, X., Li, W., Udan, R.S., Yang, Q., Kim, J., et al., 2007. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & Development 21(21):2747–2761. https://doi.org/10.1101/gad.1602907.

[37] Hansen, C.G., Ng, Y.L.D., Lam, W.L.M., Plouffe, S.W., Guan, K.L., 2015. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Research 25(12):1299–1313. https://doi.org/10.1038/cr.2015.140.

[38] Varelas, X., 2014. The hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Cambridge: Development. p. 1614–26. https://doi.org/10.1242/dev.102376.

[39] Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Guaranta, E., Bodega, B., et al., 2015. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nature Cell Biology 17(9):1218–1227. https://doi.org/10.1038/ncb3216.

[40] Kamura, K., Shih, J., Kiyonari, H., Abe, T., Shiöi, G., Fukuhara, A., et al., 2018. Obesity in YAP transgenic mice is associated with TAZ downregulation. Biochemical and Biophysical Research Communications 505(3):951–957. https://doi.org/10.1016/j.bbrc.2018.10.037.

[41] Jing, X., Wang, J., Yin, W., Li, G., Fang, Z., Zhu, W., et al., 2018. Proliferation and differentiation of rat adipose-derived stem cells are regulated by yas-associated protein. International Journal of Molecular Medicine 42(3):1526–1536. https://doi.org/10.3892/imm.2018.9724.

[42] Deng, K., Ren, C., Fan, Y., Fang, J., Zhang, G., Zhang, Y., et al., 2019. YAP1 regulates PPARγ and ROR alpha expression to affect the proliferation and differentiation of ovine preadipocyte. Journal of Cellular Biochemistry 120(12):19578–19589. https://doi.org/10.1002/jcb.20265.

[43] Crewe, C., An, Y.A., Scherer, P.E., 2017. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. Journal of Clinical Investigation, 74–82. https://doi.org/10.1172/JCI88883.

[44] Gregoire, F.M., Smas, C.M., Sul, H.S., 1998. Understanding adipocyte differentiation. Physiological Reviews, 783–809. https://doi.org/10.1152/physrev.1998.78.3.783.

[45] Sethi, J.K., Vidal-Puig, A.J., 2007. Thematic review series: adipocyte Biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. Journal of Lipid Research 48(6):1253–1262. https://doi.org/10.1194/jlr.R700005-JLR200.

[46] Song, S., Ajani, J.A., Honjo, S., Manu, D.M., Chen, Q., Scott, A.W., et al., 2014. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal Cancer cells with stem-like properties. Cancer Research 74(15):4170–4182. https://doi.org/10.1158/0008-5472.CAN-13-3569.

[47] Brodowska, K., Al-Moujahed, A., Marmalidou, A., Meyer zu Horste, M., Cichy, J., Miller, J.W., et al., 2014. The clinically used photosensitizer Verterofin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Experimental Eye Research 124:67–73. https://doi.org/10.1016/j.exer.2014.04.011.

[48] Liu-Chittenden, Y., Huang, B., Shim, J.S., Chen, Q., Lee, S.J., Anders, R.A., et al., 2012. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & Development 26(12):1300–1305. https://doi.org/10.1101/gad.192856.112.